- Argentina fires head of navy over submarine tragedy
- Egyptian presidential hopeful apologizes to arrested supporters
- Argentina fires head of navy after submarine tragedy
- Canadian police probe mysterious deaths of billionaire pharma couple
- Nazareth Christmas celebrations will be held as normal: mayor
- Libyan coast guard rescues more than 250 migrants trying to reach Ital
- It looks like tax reform is already paying off with the GOP base
- Thousands of Romanians mourn former king Michael
- Sexual harassment allegations swirl around ESPN
- Report: Toronto billionaire and his wife found dead in their home
- Austrian conservatives bring far right into government
- Russian and French foreign ministers discussed situation in Syria
- Australian PM future safeguarded in crucial Sydney by-election
- Palestinian billionaire Masri detained in Saudi Arabia: sources
- Myanmar journalists' group to don black T-shirts over arrest of Reuter
- Dustin Hoffman accused of sexual assault
- Facebook worries it might be bad for you, adds a mute button
- U.S. says did everything possible to help Italy cyber investigation
- Thai tour guide arrested for inappropriate behavior at Buddhist temple
- Roche, Shire court fight escalates over haemophilia drug
Hungary's Richter says no link seen between Esmya drug and liver damage
BUDAPEST (Reuters) - Hungarian drugmaker Richter’s clinical data for its uterine fibroid treatment Esmya indicate no demonstrable link with liver damage, the firm said on Monday.
The European Medicines Agency (EMA) has opened a review into Esmya after four reports of serious liver damage in patients treated with the drug, three of which ended up requiring liver transplants.
“Based on the clinical data at our disposal, we consider that there is no demonstrable link between liver damage and treatment with Esmya,” spokeswoman Zsuzsa Beke said, adding that Richter believed the product should not be suspended.
The uncertainty around the medicine, which Richter expects to bring in 85 million euros of revenue this year, hit the company’s share price, which touched 8-1/2-month lows of 6,371 forints in early trade. At 1125 GMT the shares were down by over 5 percent at 6,456 forints.
“Given the seriousness of the observed liver injury and its possible link to the medicine, a more in-depth review is warranted,” the EMA said in a statement on its website.
The body said its risk assessment committee would look at all available data and determine whether there were any implications for the use of Esmya, which accounted for about 6 percent of Richter’s total revenues in the first nine months of this year.
Beke said Richter was fully cooperating with the EMA, adding that currently about 670,000 patients were being treated with Esmya, first authorized in the EU in 2012 for the treatment of moderate to severe symptoms of uterine fibroids.
Beke said additional factors, such as the affected patients being treated concurrently with other medicines, or viral infections, could have contributed to the reported cases of liver damage.
Reporting by Gergely Szakacs and Marton Dunai; Editing by Edmund Blair, Greg Mahlich
Our Standards:The Thomson Reuters Trust Principles.